Symbol="ALLO"
AssetType="Common Stock"
Name="Allogene Therapeutics Inc"
Description="Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California."
CIK="1737287"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="612536000"
EBITDA="-344372992"
PERatio="None"
PEGRatio="None"
BookValue="3.727"
DividendPerShare="0"
DividendYield="0"
EPS="-2.27"
RevenuePerShareTTM="0.001"
ProfitMargin="0"
OperatingMarginTTM="-1866.93"
ReturnOnAssetsTTM="-0.261"
ReturnOnEquityTTM="-0.498"
RevenueTTM="192000"
GrossProfitTTM="243000"
DilutedEPSTTM="-2.27"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.488"
AnalystTargetPrice="16.81"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4133.63"
PriceToBookRatio="1.508"
EVToRevenue="2674.75"
EVToEBITDA="-2.221"
Beta="0.738"
num_52WeekHigh="17.23"
num_52WeekLow="4.12"
num_50DayMovingAverage="5.07"
num_200DayMovingAverage="6.47"
SharesOutstanding="145842000"
DividendDate="None"
ExDividendDate="None"
symbol="ALLO"
open="4.17"
high="4.28"
low="4.12"
price="4.20"
volume="972822.00"
latest_trading_day="2023-08-11"
previous_close="4.21"
change="-0.01"
change_percent="-0.2375%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="82"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="18"
Volume_recent_avg="2437271"
Change_recent_avg="-0.02"
Delta_recent_avg="0.36"
Variance_recent_avg="0.18"
Change_ratio_recent_avg="-0.58"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="18"
Aroon_momentum_negative="82"
image_negative_thumbnail_id_1="134"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0042.jpeg"
image_negative_thumbnail_id_2="508"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0097.jpeg"
image_neutral_thumbnail_id_1="546"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0053.jpeg"
image_neutral_thumbnail_id_2="541"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0058.jpeg"
image_positive_thumbnail_id_1="692"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0016.jpeg"
image_positive_thumbnail_id_2="1005"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0167.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1171"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
